Welcome to our dedicated page for Axcelis Tech Ord news (Ticker: ACLS), a resource for investors and traders seeking the latest updates and insights on Axcelis Tech Ord stock.
Axcelis Technologies Inc (NASDAQ: ACLS) delivers critical ion implantation systems and semiconductor manufacturing solutions to leading global chipmakers. This page provides investors and industry professionals with a centralized hub for official company announcements, operational updates, and strategic developments.
Access timely updates including earnings reports, product launches, technology partnerships, and service expansions. Our curated collection ensures you stay informed about ACLS's role in advanced logic, silicon carbide processing, and semiconductor equipment innovation.
Discover press releases covering operational milestones, customer collaborations, and advancements in process control technologies. All content is verified for accuracy and relevance to support informed analysis of ACLS's market position and industry contributions.
Bookmark this page for direct access to Axcelis Technologies' latest news. Check regularly for updates on equipment deployments, aftermarket service initiatives, and strategic developments shaping semiconductor manufacturing.
Axcelis Technologies reported strong financial guidance for Q4 2022, anticipating revenue exceeding $250 million, surpassing previous estimates of $232-$240 million. For the full year 2022, revenue is expected to exceed $900 million, with earnings per diluted share anticipated to be over $1.45 in Q4 and exceed $5.00 for the full year. CEO Mary Puma emphasized robust customer demand for the Purion product family, hinting at year-over-year growth in 2023, supported by favorable foreign exchange impacts on earnings.
Axcelis Technologies (Nasdaq: ACLS) announced its participation in the 25th Annual Needham Growth Conference, scheduled for January 10-11, 2023, at the Lotte New York Palace Hotel and virtually on January 12, 2023. The company will present on January 11th at 2:15 p.m. EST, with management available for one-on-one meetings. A live webcast will be accessible from Axcelis' website, with a replay available for 30 days after the event. Axcelis has been a key player in the semiconductor industry for over 40 years, focusing on ion implantation systems.
Axcelis Technologies (Nasdaq: ACLS) announced multiple shipments of the Purion Dragon™ high current implanter, including a follow-on order and a new customer evaluation aimed at semiconductor manufacturers in Asia. These shipments are part of Q4 2022 activities and support advanced memory and logic device development. Executive VP Greg Redinbo emphasized the Purion Dragon's capabilities, highlighting its advanced process control and productivity gains for high current applications. This move reinforces Axcelis' commitment to innovation in the semiconductor industry.
Axcelis Technologies (Nasdaq: ACLS) will showcase its innovative Purion and GSD Ovation Series ion implanters at SEMICON Japan 2022, held from December 14-16 in Tokyo. The event aims to highlight technologies that support power device, image sensor, memory, and logic markets. Key products include the Purion Power Series for silicon processing and the Purion XE Series with Boost Technology for advanced image sensors. Axcelis aims to expand its market share in Japan by meeting the increasing demand from chipmakers with these advanced solutions.
Axcelis Technologies (NASDAQ: ACLS) will participate in the 11th Annual NYC Summit on December 13, 2022, in New York City. The event features small group meetings between investors and company management teams. Presentation materials will be accessible on Axcelis' investor page. The NYC Summit is invitation-only for accredited investors and research analysts, with RSVP required by December 1, 2022. Axcelis has a strong track record in providing ion implantation solutions for the semiconductor industry, serving the market for over 40 years.
On Nov. 17, 2022, Axcelis Technologies (Nasdaq: ACLS) announced its founding membership in the Semiconductor Climate Consortium (SCC), aimed at combating climate change within the semiconductor industry. President and CEO Mary Puma emphasized this membership enhances Axcelis' sustainability efforts through collaboration. The SCC focuses on pooling industry resources to tackle decarbonization challenges and sets collective sustainability goals. Axcelis has over 40 years of experience in providing innovative ion implantation solutions critical to integrated circuit manufacturing.
On November 10, 2022, Axcelis Technologies (Nasdaq: ACLS) announced significant new shipments of its Purion Power Series ion implanter systems to various fabs in Asia and Europe. This includes the first SiC tool shipped from their South Korea operations. Key models shipped are the Purion H200, Purion XE, and Purion M, aimed at high-volume production of Si and SiC power devices. CEO Mary Puma highlighted continued growth in the power device market and emphasized the company's technological advantages and market share prospects.
Axcelis Technologies reported a strong financial performance in Q3 2022, with revenue of $229.2 million, up from $221.2 million in Q2. Operating profit decreased slightly to $53.2 million, while net income was $40.3 million, or $1.21 per diluted share, down from $44.2 million or $1.32 per diluted share. Gross margin improved to 45.1%. The company also reported a record systems backlog of $1.1 billion and booking of $337.1 million. For Q4 2022, Axcelis expects revenue of $232-240 million and operating profit of $41-45 million.
Axcelis Technologies (Nasdaq: ACLS) announced shipments of its PurionH™ and PurionXE™ implanters to a major analog chip manufacturer in North America. This follows a series of multi-year purchase orders aimed at enhancing the chipmaker's manufacturing capabilities. CEO Mary Puma highlighted the customer's confidence in Axcelis, reflecting strong business relationships.
The company has over 40 years of experience in the semiconductor sector, focusing on high-productivity solutions and support for critical ion implantation processes.